AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15816472
Drug: Conventional antiviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional antiviral treatment (pegylated interferon alpha and ribavirin) after 3 months
Trial: 6369669
Drug: High-dose steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose steroids with azathioprine
Trial: 6369669
Drug: Low-dose steroids
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose steroids with azathioprine
Trial: 16536341
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L‐Pop (APLP)
Trial: 16536341
Drug: Prompt L‐Pop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt L‐Pop 2 (PLP)
Trial: 3521518
Drug: Oral bacitracin
RxNorm normalized name: Bacitracin
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral bacitracin
Trial: 26379068
Drug: HIV-1 Gag-
RxNorm normalized name: GAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 Gag- and Nef-transfected DCs (vaccine)
Trial: 21275332
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (MT) sessions multiple times per week
Trial: 12941198
Drug: Recent advances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent advances in biologic response modifier therapy
Trial: 10230954
Drug: Amrinone (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrinone (loading dose of 2 mg/kg, maintenance infusion of 7.5 microg/kg/min)
Trial: 8674002
Drug: Second-line hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second-line hormonal therapy with megestrol acetate or fadrozole
Trial: 1688356
Drug: Ambroxol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (1 g/day intravenously for 6 consecutive days)
Trial: 7017343
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at a rate of 0.33 mU/kg/min
Trial: 7017343
Drug: No insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No insulin infusion (control)
Trial: 31553457
Drug: NKTR-181 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-181 400 mg
Trial: 31553457
Drug: NKTR-181 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-181 600 mg
Trial: 31553457
Drug: NKTR-181 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-181 400 mg and 600 mg
Trial: 20386884
Drug: Oxycodone 40
RxNorm normalized name: ibuprofen-oxycodone 400 mg-5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 40 mg
Trial: 29265090
Drug: Tolpersione injection
RxNorm normalized name: tolperisone
DrugBank: Tolperisone (DB06264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolpersione injection and oral formulations combined with NSAID
Trial: 29265090
Drug: NSAID monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID monotherapy
Trial: 25453481
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose exercise regimen
Trial: 25453481
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose exercise regimen
Trial: 18637782
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of enteric-coated aspirin tablets daily
Trial: 14998110
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management (MedMgt)
Trial: 15060224
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Comb)
Trial: 15060224
Drug: Behavior modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior modification therapy (Beh)
Trial: 15060224
Drug: Usual community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual community comparison (CC)
Trial: 11753057
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection with rehabilitation
Trial: 11753057
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection with rehabilitation
Trial: 8480506
Drug: Isradipine (0.0010,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (0.0010, 0.0020, 0.0040, 0.0080 mg.kg‐1; total 0.0150 mg.kg‐1)
Trial: 8480506
Drug: Verapamil (0.0125,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (0.0125, 0.0250, 0.0500, 0.1000 mg.kg‐1; total 0.1875 mg.kg‐1)
Trial: 22367114
Drug: Rebamipide (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide (15 mg, t.i.d. for 4 weeks)
Trial: 20162245
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose dobutamine infusion
Trial: 17192164
Drug: Ramelteon (melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon (melatonin receptor agonist)
Trial: 17192164
Drug: Benzodiazepine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine and nonbenzodiazepine sedative-hypnotic agents
Trial: 17192164
Drug: Sedating antihistamines
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedating antihistamines
Trial: 17192164
Drug: Melatonin (herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (herbal preparation)
Trial: 17192164
Drug: Valerian (herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian (herbal preparation)
Trial: 17192164
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (nonpharmacologic option)
Trial: 17192164
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy (nonpharmacologic option)
Trial: 12404219
Drug: Aspirin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (500 mg 3 times daily) for 5 days
Trial: 12404219
Drug: Aspirin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (5 days)
Trial: 31499384
Drug: Active supportive
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active supportive care (ASC) + oral erlotinib
Trial: 25913109
Drug: Δ(9)-THC at
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Δ(9)-THC at .015 mg/kg
Trial: 25913109
Drug: Δ(9)-THC at
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Δ(9)-THC at .03 mg/kg
Trial: 25913109
Drug: Δ(9)-THC (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Δ(9)-THC (both doses)
Trial: 20610478
Drug: RPE cell‐suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPE cell‐suspension transplantation (group 2)
Trial: 19283647
Drug: Other anticonvulsants
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other anticonvulsants
Trial: 15061348
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment experts
Trial: 11210393
Drug: Eniporide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eniporide (2.5 to 100 mg, administered intravenously)
Trial: 7800183
Drug: Ventilatory setting
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ventilatory setting with constant tidal volume (VC = 8 ml.kg‐1) and varying respiratory frequencies (f = 10, 12, and 14 breaths.min‐1)
Trial: 7800183
Drug: Constant ventilation
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant ventilation (112 ml.kg‐1) with modified VC and f
Trial: 29315699
Drug: Regorafenib eye
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib eye drops (30 mg ml-1, 25 μl) as a 0.75 mg single dose (Cohort 1)
Trial: 29315699
Drug: Regorafenib eye
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib eye drops (0.75 mg twice daily for 14 days, Cohort 2)
Trial: 29315699
Drug: Regorafenib eye
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib eye drops (0.75 mg thrice daily for 14 days, Cohort 3)
Trial: 29315699
Drug: Regorafenib eye
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib eye drops (1.5 mg thrice daily unilaterally for 3 days, then bilaterally for up to 14 days, Cohort 4)
Trial: 29315699
Drug: Regorafenib eye
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib eye drops (0.75 mg)
Trial: 29315699
Drug: Regorafenib eye
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib eye drops (up to 30 mg ml-1 tid)
Trial: 12577163
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of tramadol (20 mg/ml) and dipyrone (200 mg/ml)
Trial: 12577163
Drug: Patient controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled analgesia (PCA) with tramadol (20 mg/ml) and dipyrone (200 mg/ml)
Trial: 12577163
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of tramadol and dipyrone
Trial: 10858338
Drug: Nelfinavir at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir at a dose of 500 or 750 mg three times a day
Trial: 10858338
Drug: Nelfinavir with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir with concomitant fluconazole therapy
Trial: 10858338
Drug: Nelfinavir without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir without fluconazole therapy
Trial: 19473225
Drug: Glutamate supplementation
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate supplementation (500 mg three times daily)
Trial: 17899046
Drug: BAY 63‐9044
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 63‐9044 (0.25 mg, 0.5 mg, 1.2 mg, 2.5 mg, 5.0 mg)
Trial: 17899046
Drug: BAY 63‐9044
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 63‐9044 (0.5 mg)
Trial: 17899046
Drug: BAY 63‐9044
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 63‐9044 (1.2 mg)
Trial: 17899046
Drug: BAY 63‐9044
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 63‐9044 (highest two doses)
Trial: 8877724
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide 300 mg/m2 on day -3
Trial: 8877724
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide 50 mg daily from days -14 to -3
Trial: 3972647
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy (Dextran, Diazepam, and Vitamins)
Trial: 27356642
Drug: Automated intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated intermittent boluses of 10 ml of 0.2% ropivacaine every 60 mins for 48 hours
Trial: 27356642
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 10 ml/h of 0.2% ropivacaine for 48 hours
Trial: 22850709
Drug: Latex membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latex membrane implant
Trial: 22850709
Drug: Sylastic® membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sylastic® membrane implant
Trial: 22850709
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no transitory implant
Trial: 12913186
Drug: KW-6002 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-6002 (80 mg)
Trial: 1614072
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (enalapril 5 mg + felodipine 5 mg)
Trial: 1614072
Drug: Felodipine 5
RxNorm normalized name: felodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5 mg added to enalapril 5 mg
Trial: 1614072
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg added to felodipine 5 mg
Trial: 6599697
Drug: Nifedipine, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 3 X 10‐20 mg/day
Trial: 6599697
Drug: Nifedipine +
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine + chlorthalidone, 25 to 50 mg/day
Trial: 31250880
Drug: Palbociclib at
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib at 125 mg daily, 3 weeks on/1 week off for 2 years
Trial: 27277115
Drug: Chlorophyll c2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorophyll c2 (0.7 mg daily for 12 weeks)
Trial: 23684697
Drug: No oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No oxytocin augmentation
Trial: 20420787
Drug: Fesoterodine 28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 28 mg
Trial: 18611271
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) administered twice at eight-week intervals during the transmission season.
Trial: 18611271
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) during the first 16 weeks of follow-up.
Trial: 18611271
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) during the subsequent transmission season.
Trial: 18611271
Drug: In vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo response to treatment with SP.
Trial: 12124559
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with additional antioxidants (Allopurinol, vitamin E and C, N‐acetylcysteine, and mannitol)
Trial: 1769413
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 250 mg, twice daily for 10 days
Trial: 1769413
Drug: Cephalexin 500
RxNorm normalized name: cephalexin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 500 mg, twice daily for 10 days
Trial: 1769413
Drug: Cefadroxil 500
RxNorm normalized name: cefadroxil 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil 500 mg, twice daily for 10 days
Trial: 25575502
Drug: Randomized drug
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized drug treatment in mild-to-moderate hypertension
Trial: 19321506
Drug: Intranasal diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal diamorphine plus intravenous morphine
Trial: 19321506
Drug: Intranasal diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal diamorphine plus oral morphine
Trial: 17125605
Drug: Telbivudine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 200 mg
Trial: 17125605
Drug: Telbivudine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 400 mg
Trial: 17125605
Drug: Telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 600 mg (single dose)
Trial: 17125605
Drug: Telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 600 mg (multiple doses for 8 days)
Trial: 17125605
Drug: Telbivudine 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 800 mg
Trial: 11738277
Drug: Daily 400-microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 400-microg folic acid supplement plus natural diet
Trial: 9286744
Drug: Candy bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candy bar (C1: 280 kcal, 36 g CHO)
Trial: 9286744
Drug: Fat-free fig
RxNorm normalized name: Fig
DrugBank: Fig (DB10633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat-free fig bars (C2: 200 kcal, 44 g CHO)
Trial: 3520795
Drug: 10-15 mg
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-15 mg prednisone daily
Trial: 26517404
Drug: Electronic reading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic reading (tablet and computer display at 100% and 330% zoom levels)
Trial: 20656516
Drug: Cerebrolysin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin 20 mL administered once daily for 24 weeks
Trial: 19473603
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tramadol extended-release capsules taken in the fasted state between 7:30 and 8:00 a.m.
Trial: 19473603
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tramadol extended-release capsules taken in the fasted state between 7:30 and 8:00 p.m.
Trial: 19473603
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tramadol extended-release capsules taken in the fasted state between 7:30 and 8:00 a.m. or p.m.
Trial: 15259895
Drug: Lamivudine alone
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine alone (150 mg/day for 96 weeks)
Trial: 852337
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: Isoniazid (5 to 6 mg/kg), Ethambutol (25 mg/kg), Rifampin (10 mg/kg) daily for 6 months
Trial: 852337
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: Same therapy as group 1 for 6 months, then Isoniazid (5 mg/kg three days per week) for an additional 6 months
Trial: 16619360
Drug: STA-1 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STA-1 (80 g/kg/day, administered twice daily for 6 months)
Trial: 16619360
Drug: Placebo (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (80 g/kg/day, administered twice daily for 6 months)
Trial: 12791625
Drug: Active group
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active group (234 mg cocoa flavanols and procyanidins/d)
Trial: 12791625
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (<= 6 mg cocoa flavanols and procyanidins/d)
Trial: 9153458
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) 100, 200, or 400 mg
Trial: 9153458
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) titrated up to 400 mg
Trial: 7957540
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg dexfenfluramine taken with 250 ml water
Trial: 7957540
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg fluoxetine pretreatment at -8 h
Trial: 7957540
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg fluoxetine daily for 14 days
Trial: 7957540
Drug: Dexfenfluramine alone
RxNorm normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine alone 14 days after cessation of 14 days of fluoxetine treatment
Trial: 3588052
Drug: Cisapride (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (0.3 mg/kg initial dose, followed by 0.15 mg/kg every 4 hr for 12 hr)
Trial: 18940401
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise (6-month program with weekly training sessions)
Trial: 12912818
Drug: Methionine-loading test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine-loading test (100 mg/kg body weight, administered orally)
Trial: 10825325
Drug: 0.08% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.08% bupivacaine plus 2 microg/mL fentanyl (BF)
Trial: 10825325
Drug: 0.08% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.08% ropivacaine plus 2 microg/mL fentanyl (RF)
Trial: 27072546
Drug: High G
RxNorm normalized name: ONE TOUCH HIGH GLUCOSE CONTROL SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High G tolerance group (H group)